Professor David Nutt is a world famend neuroscientist, main world authority on drug coverage reform and former chief drug advisor to the UK authorities. He serves because the Edmond J. Safra Professor of Neuropsychopharmacology and director of the neuropsychopharmacology unit within the Division of Brain Sciences at Imperial College London, and Founding Chair of Drug Science (previously the Independent Scientific Committee on Drugs).

AWAKN’s SAB will present strategic scientific counsel as the corporate implements its imaginative and prescient and technique throughout three enterprise strains of scientific analysis, therapeutic clinics and healthcare coaching.

Dr. Ben Sessa, AWAKN Chief Medical Officer, said: “David has always been a trailblazer and supporter of innovative psychopharmacology. He is a prolific promoter of drug reform policies and an internationally respected scientific researcher. I have had the pleasure of working alongside David on numerous psychedelic studies over the last 10 years, and we know the time is right and the time is now. David shares AWAKN’s vision of how clinical psychedelics in combination with psychotherapy can cure mental health conditions. This is a new way of doing psychiatry. This is the medicine of the future.”

Prof. David Nutt, AWAKN Scientific Advisory Board Chair, said: “I am delighted to be able to support this exciting initiative. I believe psychedelic treatments have the opportunity to change psychiatry in the way immunotherapies are changing medicine. The sooner we can start using these the better it will be for patients, and I am pleased AWAKN are taking the lead in this.”

Anthony Tennyson, AWAKN CEO, said: “What a time this is for psychedelic medicine. An era of scientific and therapeutic innovation with real potential to move the dial on mental health care. Professor Nutt encapsulates the essence of scientific change, and we are honored to welcome such global pedigree to the mix alongside his longtime friend and collaborator, our Chief Medical Officer, Dr. Ben Sessa.”

About Professor David Nutt

Prof. David Nutt is presently the Edmond J. Safra Professor of Neuropsychopharmacology and Director of the Neuropsychopharmacology Unit within the Division of Brain Sciences.

After 11+ entry to Bristol Grammar School David was awarded an Open Scholarship to Downing College Cambridge after which accomplished his medical coaching at Guy’s Hospital London, persevering with in neurology to MRCP. After finishing his psychiatric coaching in Oxford, he continued there as a lecturer after which later as a Wellcome Senior Fellow in psychiatry. He then spent two years as Chief of the Section of Clinical Science within the National Institute of Alcohol Abuse and Alcoholism in NIH, Bethesda, USA. On returning to England in 1988 he arrange the Psychopharmacology Unit in Bristol University, an interdisciplinary analysis grouping spanning the departments of Psychiatry and Pharmacology earlier than shifting to Imperial College London in December 2008 the place he leads the same group with a specific concentrate on mind imaging particularly PET.

David is presently Chair of DrugScience (formally the Independent Scientific Committee on Drugs (ISCD)). He was beforehand President of the European Brain Council, the European College of Neuropsychopharmacology (ECNP), the British Neuroscience Association (BNA) and the British Association of Psychopharmacology (BAP). He is a Fellow of the Royal Colleges of Physicians and of Psychiatrists and of the Academy of Medical Sciences. He can also be the UK Director of the European Certificate and Masters in Affective Disorders Courses and a member of the International Centre for Science in Drug Policy. He has edited the Journal of Psychopharmacology for over twenty years and acts because the psychiatry medicine advisor to the British National Formulary. He has revealed over 500 unique analysis papers, the same variety of critiques and books chapters, eight authorities studies on medicine and 33 books.

Previously he has been a member after which Chair of the Advisory Committee on the Misuse of Drugs (ACMD – 1998-2009), a member of the HEFCE/NHS Senior Lecturer Selection Panel and of the MRC Neuroscience Board. Other earlier nationwide contributions embody serving because the medical knowledgeable on the Independent Inquiry into the Misuse of Drugs Act (2000 Runciman report), and membership of the Committee on Safety of Medicines, the Committee on NHS medicine and the Ministry of Defence Science Advisory Board. He was the scientific scientific lead on the 2004/5 UK Government Foresight initiative “Brain science, addiction and drugs” that supplied a 25-year imaginative and prescient for this space of science and public coverage.

David broadcasts broadly to most people each on radio and tv together with BBC science and public affairs programmes on therapeutic in addition to illicit medicine, their harms and their classification. He additionally lectures broadly to the general public in addition to to the scientific and medical communities; for example has offered thrice on the Cheltenham Science Festival and several other instances for Café Scientifiques. In 2010 The Times Eureka science journal included him within the 100 most essential figures in British Science, and the one psychiatrist.

About AWAKN Life Sciences

AWAKN Life Sciences Inc. supplies evidence-based Psychedelic Assisted Psychotherapy options to heal psychological well being situations. We work throughout three enterprise strains of scientific analysis, therapeutic clinics and healthcare coaching. Our focus is guaranteeing optimum affected person security, whereas delivering efficacy by way of transformative affected person care, along side scientifically validating long-term psychological well being.

https://www.psychedelicfinance.com/articles/professor-david-nutt-joins-awakn-life-sciences?utm_source=Prohibition+Partners+-+PSYCH+Audience&utm_campaign=946fc597cb-EMAIL_CAMPAIGN_2020_07_01_03_11_COPY_01&utm_medium=email&utm_term=0_612b653a0d-946fc597cb-78839905#subscribe

Source link